Emerging treatments

Antiviral agents and vaccines

Various vaccines are in development, including purified inactivated viral (PIV) particles, purified virus-like particles (VLPs) and viral subunit proteins, live-attenuated vaccines, chimeric vaccines, and viral and nonviral vectors encoding Zika virus structural proteins. [207] [208] [209]  Zika purified inactivated virus (ZPIV) vaccine, an investigational vaccine, has started clinical trials to test safety and efficacy in the US. [136] A synthetic DNA vaccine (GLS-500) has shown promise in a phase I trial. [210] A live-attenuated vaccine has also shown promise in animal studies. [211] While there are currently no specific antiviral treatments available for Zika virus infection, various candidates are being trialed in early-stage trials. [212] [213] Antiviral agents effective against the hepatitis C virus are being tested and have shown activity against Zika virus polymerase. [214] Selected antimalarial drugs have shown activity against Zika virus. [215] A new mouse model may help in exploring the potential activity of Zika virus vaccines and therapeutics. [216]

Use of this content is subject to our disclaimer